The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Open accessPublished version of a preprint
Abstract
Immunotherapeutic PD-1–targeted therapies require CD28 to promote cancer cell killing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ligation of PD-1 with its ligands programmed death-ligand 1 or 2 (PD-L1 or PD-L2) induces tyrosine phosphorylation of the PD-1 cytoplasmic domain by phosphorylating kinase Lck and subsequent recruitment of cytosolic tyrosine phosphatase SHP-2 and PD-1-associated SHP-2 preferentially dephosphorylates CD28 and suppresses CD28 costimulatory signaling leading to restrained effector T cell function (49”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [49]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Overcoming such checkpoints through the use of therapeutic antibodies targeting the CTLA-4, PD-1, or PD-L1 cell-surface receptors was shown to be instrumental in promoting anti-tumor T cell responses in mice and in cancer patients”
From LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer (2018) · cites this paper as Hui et al., 2017
Experimental — accuracy not yet measuredIn the citing paper
“SHP2 also has effects on parallel pathways (e.g., JAK/STAT signaling) and is implicated as an effector of inhibitory signaling by PD-1 and some other immune checkpoint receptors (Hui et al., 2017; Peled et al., 2018; Yokosuka et al., 2012).”
From SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling (2021) · cites this paper as Hui et al., 2017
In the citing paper
“Among these, CD28 has recently been found to be the primary target (45).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [45]
In the citing paper
“The requirement for both T cell co-stimulation and IL-12 to achieve maximal IFN-γ response likely reflected the need of CD28 to rescue exhausted CD8+ T cells, and possibly also the role of PD-1 in limiting CD28-mediated co-stimulation (Kamphorst et al., 2017; Hui et al., 2017).”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Hui et al., 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Self-citationPD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Self-citationTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Cited by
Sorted by citations
Items 501–600 of 1,002
Parra, E. R., Zhang, J., Duose, D. Y., Gonzalez‐Kozlova, E., Redman, M. W., Chen, H., Manyam, G. C., Kumar, G., Zhang, J., Song, X., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0251 · Cited by 43
New therapeutic strategies based on IL-2 to modulate Treg cells for autoimmune diseases
Xu, L., Song, X., Su, L., Zheng, Y., Li, R., & Sun, J. M. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.03.064 · Cited by 43
Revving the CAR – Combination strategies to enhance CAR T cell effectiveness
Bansal, R., & Reshef, R. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100695 · Cited by 42
The CoV-2 outbreak: how hematologists could help to fight Covid-19
Galimberti, S., Baldini, C., Baratè, C., Ricci, F., Balducci, S., Grassi, S., Ferro, F., Buda, G., Benedetti, E., Fazzi, R., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104866 · Cited by 41
Xu, X., Guo, Q., Cui, C., Lin, Y., Zhang, L. J., Ding, X., Li, Q., Wang, M., Yang, W., Kong, Y., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00197-2 · Cited by 46
Antitumor Immune Responses in B2M -Deficient Cancers
Torrejon, D. Y., Galvez, M., Abril-Rodríguez, G., Campbell, K. M., Medina, E., Vega-Crespo, A., Kalbasi, A. K., Comı́n-Anduix, B., & Ribas, A. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0139 · Cited by 43
McGinnis, G. J., & Raber, J. (2017) · Immunotherapy · doi:10.2217/imt-2017-0056 · Cited by 42
Jiang, H., Shin, D. H., Nguyen, T. T., Fueyo-Margareto, J., Fan, X., Henry, V. K., Carrillo, C. C., Yi, Y., Alonso, M. M., Collier, T. L., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0405 · Cited by 40
Development of natural products for anti-PD-1/PD-L1 immunotherapy against cancer
Ri, M., Ma, J., & Jin, X. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114370 · Cited by 41
Mi, Y., Han, J., Zhu, J., & Jin, T. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02495-7 · Cited by 43
Self-citationDifferential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response
Gangaev, A., Rozeman, E. A., Rohaan, M. W., Isaeva, O. I., Philips, D., Patiwael, S., van den Berg, J. H., Ribas, A., Schadendorf, D., Schilling, B., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102849118 · Cited by 41
A variety of ‘exhausted’ T cells in the tumor microenvironment
Nagasaki, J., & Togashi, Y. (2022) · International Immunology · doi:10.1093/intimm/dxac013 · Cited by 43
Wang, R., He, S., Long, J., Wang, Y., Jiang, X., Chen, M., & Wang, J. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00515-5 · Cited by 43
Strategies of Combination Drug Delivery for Immune Checkpoint Blockades
Ruan, H., Bu, L., Hu, Q., Cheng, H., Lu, W., & Gu, Z. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201801099 · Cited by 40
If small molecules immunotherapy comes, can the prime be far behind?
Zhang, J., Zhang, Y., Qu, B., Yang, H., Hu, S., & Dong, X. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113356 · Cited by 40
Inflammasomes in dendritic cells: Friend or foe?
Hatscher, L., Amon, L., Heger, L., & Dudziak, D. (2021) · Immunology Letters · doi:10.1016/j.imlet.2021.04.002 · Cited by 40
Greene, E., Finak, G., D’Amico, L., Bhardwaj, N., Church, C. D., Morishima, C., Ramchurren, N., Taube, J. M., Nghiem, P., Cheever, M. A., et al. (2021) · Patterns · doi:10.1016/j.patter.2021.100372 · Cited by 40
Wang, Q., Bardhan, K., Boussiotis, V. A., & Patsoukis, N. (2021) · Advanced Biology · doi:10.1002/adbi.202100758 · Cited by 39
Graham, R. A., Gazińska, P., Zhang, B., Khiabany, A., Sinha, S., Alaguthurai, T., Flores‐Borja, F., Vicencio, J. M., Beuron, F., Roxanis, I., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1204224 · Cited by 39
Liquid‒liquid phase separation: roles and implications in future cancer treatment
Liu, Z., Qin, Z., Liu, Y., Xia, X., He, L., Chen, N., Hu, X., & Peng, X. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.81521 · Cited by 38
CD4+ T-cell subsets in autoimmune hepatitis: A review
Chen, H., Han, Z., Fan, Y., Chen, L., Peng, F., Cheng, X., Wang, Y., Su, J., & Li, D. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000269 · Cited by 41
Checks and Balances in Autoimmune Vasculitis
Cadena, R. H., Abdulahad, W. H., Hospers, G. A. P., Wind, T. T., Boots, A. M. H., Heeringa, P., & Brouwer, E. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00315 · Cited by 39
Immunoadjuvant therapy in sepsis: novel strategies for immunosuppressive sepsis coming down the pike
Watanabe, E., Thampy, L. K., & Hotchkiss, R. S. (2018) · Acute Medicine & Surgery · doi:10.1002/ams2.363 · Cited by 39
Snook, J. P., Soedel, A. J., Ekiz, H. A., O’Connell, R. M., & Williams, M. A. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0690 · Cited by 41
Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches
Noh, J., Seo, H., Lee, J., & Jung, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218000 · Cited by 40
An allosteric interaction controls the activation mechanism of SHP2 tyrosine phosphatase
Anselmi, M., & Hub, J. S. (2020) · Scientific Reports · doi:10.1038/s41598-020-75409-7 · Cited by 39
Cintio, F. D., Bo, M. D., Baboçi, L., Mattia, E. D., Polano, M., & Toffoli, G. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.603647 · Cited by 41
Shirinbak, S., Chan, R. Y., Shahani, S. A., Muthugounder, S., Kennedy, R. J., Hung, L. T., Fernández, G. E., Hadjidaniel, M. D., Moghimi, B., Sheard, M. A., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2020.1838140 · Cited by 41
Yusof, M. N. M., Chew, K. T., Kampan, N. C., Aziz, N. H. A., Zin, R. R. M., Tan, G. C., & Shafiee, M. N. (2022) · Cancers · doi:10.3390/cancers14163911 · Cited by 38
Adjuvant therapy options in renal cell carcinoma — targeting the metastatic cascade
Fitzgerald, K. N., Motzer, R. J., & Lee, C. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00666-2 · Cited by 39
Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapy
Zhou, X., Li, C., Chen, T., Li, W., Wang, X., & Yang, Q. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01746-6 · Cited by 38
Shin, K., Kim, J., Park, S. J., Lee, M. A., Park, J. M., Choi, M., Kang, D.-H., Song, K. Y., Lee, H. H., Seo, H. S., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-33128-9 · Cited by 38
Self-citationImmune checkpoints and cancer immunotherapies: insights into newly potential receptors and ligands
Kamali, A. N., Bautista, J. M., Eisenhut, M., & Hamedifar, H. (2023) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/25151355231192043 · Cited by 43
Zhao, X., Zhang, L., Wu, N., Liu, Y., Xie, J., Su, L. F., Zhu, Q., Unger, B. H., Altaf, F., Hu, Y., et al. (2023) · Aquaculture · doi:10.1016/j.aquaculture.2023.740142 · Cited by 38
Liu, R., Zeng, L., Li, H.-F., Shi, J.-G., Zhong, B., Shu, H., & Li, S. (2023) · Cell Research · doi:10.1038/s41422-023-00890-4 · Cited by 38
Biology and function of exosomes in tumor immunotherapy
Liu, C., Xia, C., & Xia, C. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115853 · Cited by 42
Imai, D., Yoshizumi, T., Okano, S., Uchiyama, H., Ikegami, T., Harimoto, N., Itoh, S., Soejima, Y., Aishima, S., Oda, Y., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.1087 · Cited by 38
Cannons, J. L., Preite, S., Kapnick, S. M., Uzel, G., & Schwartzberg, P. L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01758 · Cited by 37
PD-1 Tumor Suppressor Signaling in T Cell Lymphomas
Wartewig, T., & Ruland, J. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.03.005 · Cited by 38
ERK Activation in CAR T Cells Is Amplified by CD28-Mediated Increase in CD3ζ Phosphorylation
Rohrs, J. A., Siegler, E. L., Wang, P., & Finley, S. D. (2020) · iScience · doi:10.1016/j.isci.2020.101023 · Cited by 36
Hernandez, C., Arasanz, H., Chocarro, L., Bocanegra, A., Zuazo, M., Fernández-Hinojal, G., Blanco, E., Vera, R., Escors, D., & Kochan, G. T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072411 · Cited by 38
T-cell Exhaustion in Organ Transplantation
Angeletti, A., Cantarelli, C., Riella, L. V., Fribourg, M., & Cravedi, P. (2021) · Transplantation · doi:10.1097/tp.0000000000003851 · Cited by 39
Spatial determinants of CD8+ T cell differentiation in cancer
Tooley, K., Escobar, G., & Anderson, A. C. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.04.003 · Cited by 38
The effect of Wnt/β-catenin signaling on PD-1/PDL-1 axis in HPV-related cervical cancer
Aghbash, P. S., Hemmat, N., Baradaran, B., Mokhtarzadeh, A., Poortahmasebi, V., Oskouee, M. A., & Baghi, H. B. (2022) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2022.026776 · Cited by 39
Becker, M. W., Peters, L. D., Myint, T. S., Smurlick, D., Powell, A., Brusko, T. M., & Phelps, E. A. (2023) · Science Advances · doi:10.1126/sciadv.adg1082 · Cited by 37
Frijlink, E., Bosma, D. M. T., Busselaar, J., Battaglia, T., Staal, M. D., Verbrugge, I., & Borst, J. G. (2024) · Journal of Clinical Investigation · doi:10.1172/jci171154 · Cited by 42
T cell senescence: a new perspective on immunotherapy in lung cancer
Huang, M., Wang, Y., Fang, L., Liu, C., Feng, F., Liu, L., & Sun, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1338680 · Cited by 37
Tarin, M., Oryani, M. A., Javid, H., & Karimi‐Shahri, M. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114519 · Cited by 38
Phosphoinositide 3‐kinase δ is a regulatory T‐cell target in cancer immunotherapy
Lim, E. L., & Okkenhaug, K. (2019) · Immunology · doi:10.1111/imm.13082 · Cited by 37
Sitaram, P., Uyemura, B. S., Malarkannan, S., & Riese, M. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235821 · Cited by 39
Cess, C. G., & Finley, S. D. (2019) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2019.110125 · Cited by 37
Targeting T Cell Activation in Immuno-Oncology
Saibil, S. D., & Ohashi, P. S. (2020) · Current Oncology · doi:10.3747/co.27.5285 · Cited by 39
Niche-specific MHC II and PD-L1 regulate CD4+CD8αα+ intraepithelial lymphocyte differentiation
Moon, S., Park, Y., Hyeon, S., Kim, Y., Kim, J., Kim, H., Park, S., Lee, K.-J., Koo, B., Ha, S., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20201665 · Cited by 37
Self-citationUnraveling the Role of Immune Checkpoints in Leishmaniasis
Silva, R. D. F. E., & von Stebut, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.620144 · Cited by 37
Li, C., Chi, H., Deng, S., Xu, K., Wang, H., Yao, H., Wang, Y., Chen, D., Guo, X., Fang, J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002443 · Cited by 39
Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications
Cabo, M., Offringa, R., Zitvogel, L., Kroemer, G., Muntasell, A., & Galluzzi, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1371896 · Cited by 37
Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity
Zhang, Y., Song, Q., Cassady, K. M., Lee, M., Tang, H., Zheng, M., Wang, B., Schones, D. E., Fu, Y., Riggs, A. D., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2205085120 · Cited by 40
Evolution of developmental and comparative immunology in poultry: The regulators and the regulated
Lu, M., Lee, Y., & Lillehoj, H. S. (2022) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2022.104525 · Cited by 43
Kennedy, A., Robinson, M. A., Hinze, C., Waters, E., Williams, C., Halliday, N., Dovedi, S. J., & Sansom, D. M. (2023) · The EMBO Journal · doi:10.15252/embj.2022111556 · Cited by 37
Metal-Organic Frameworks Applications in Synergistic Cancer Photo-Immunotherapy
Fernandes, P. D., Magalhães, F. D., Pereira, R. F., & Pinto, A. M. (2023) · Polymers · doi:10.3390/polym15061490 · Cited by 36
Immunotherapies in chronic pain through modulation of neuroimmune interactions
Zhao, J., Huh, Y., Bortsov, A. V., Diatchenko, L. B., & Ji, R. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108476 · Cited by 42
Song, Y., Wang, Y., Wang, S., Cheng, Y. S., Lu, Q., Yang, L., Tan, F., & Li, N. (2019) · Nano Research · doi:10.1007/s12274-019-2341-8 · Cited by 36
Immunotherapy in Ovarian Cancer
Wang, W., Liu, J. R., & Zou, W. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.02.002 · Cited by 36
Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy
Amon, L., Hatscher, L., Heger, L., Dudziak, D., & Lehmann, C. H. K. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12070663 · Cited by 37
The Potential of Tissue-Resident Memory T Cells for Adoptive Immunotherapy against Cancer
Beumer‐Chuwonpad, A., Taggenbrock, R. L. R. E., Ngo, T. A., & van Gisbergen, K. P. J. M. (2021) · Cells · doi:10.3390/cells10092234 · Cited by 40
Targeting RAS mutants in malignancies: successes, failures, and reasons for hope
Yang, H. S., Zhou, X., Fu, D., Le, C., Wang, J., Zhou, Q., Liu, X., Yuan, Y., Ding, K., & Xiao, Q. (2022) · 癌症：英文版 · doi:10.1002/cac2.12377 · Cited by 38
Functional differences between rodent and human PD-1 linked to evolutionary divergence
Masubuchi, T., Chen, L., Marcel, N., Wen, G. A., Caron, C., Zhang, J., Zhao, Y., Morris, G. P., Chen, X., Hedrick, S. M., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.ads6295 · Cited by 36
Self-citationMechanisms of immunogenic cell death and immune checkpoint blockade therapy
Lin, R. A., Lin, J. K., & Lin, S. (2021) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12375 · Cited by 38
Small molecule inhibitors for cancer immunotherapy and associated biomarkers – the current status
Schlicher, L., Green, L. G., Romagnani, A., & Renner, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1297175 · Cited by 34
Zhang, R., Lv, Z., Chang, L., Wang, J., Tang, J., Wang, Z., Li, S., Guo, J., Yao, C., & Yang, D. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202401563 · Cited by 35
Lentiviral Vector-Based Dendritic Cell Vaccine Suppresses HIV Replication in Humanized Mice
Norton, T. D., Zhen, A., Tada, T., Kim, J. S., Kitchen, S. G., & Landau, N. R. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.03.008 · Cited by 35
Self-citationNovel immunotherapeutic approaches for hepatocellular carcinoma treatment
Busato, D., Mossenta, M., Baboçi, L., Cintio, F. D., Toffoli, G., & Bo, M. D. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1598859 · Cited by 36
Liu, C., Hu, Q., Hu, K., Su, H., Shi, F., Kong, L., Zhu, H., & Yu, J. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1872-9 · Cited by 38
Tumor suppression of novel anti–PD-1 antibodies mediated through CD28 costimulatory pathway
Fenwick, C. W., Loredo-Varela, J.-L., Joo, V., Pellaton, C., Farina, A., Rajah, N., Esteves-Leuenberger, L., Decaillon, T., Suffiotti, M., Noto, A., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20182359 · Cited by 37
Genomic landscape of young ATLL patients identifies frequent targetable CD28 fusions
Yoshida, N., Shigemori, K., Donaldson, N. L., Trevisani, C. P., Cordero, N. A., Stevenson, K. E., Bu, X., Arakawa, F., Takeuchi, M., Ohshima, K., et al. (2020) · Blood · doi:10.1182/blood.2019001815 · Cited by 35
Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade
Hu, W., Wang, G., Wang, Y., Riese, M. J., & You, M. (2020) · iScience · doi:10.1016/j.isci.2020.101580 · Cited by 35
The Role of T Cell Receptor Signaling in the Development of Type 1 Diabetes
Clark, M., Kroger, C. J., Qi, K., & Tisch, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.615371 · Cited by 37
The role of PD-L1 in the immune dysfunction that mediates hypoxia-induced multiple organ injury
Sun, Y., Tan, J., Miao, Y., & Zhang, Q. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00742-x · Cited by 36
Engineering DNA Nanostructures to Manipulate Immune Receptor Signaling and Immune Cell Fates
Tseng, C., Wang, W. X., Douglas, T. R., & Chou, L. Y. T. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202101844 · Cited by 36
PD-1/PD-L1 axis in organ fibrosis
Zhao, Y., Qu, Y., Hao, C., & Yao, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1145682 · Cited by 37
Satapathy, B. P., Sheoran, P., Yadav, R., Chettri, D., Sonowal, D., Dash, C. P., Dhaka, P., Uttam, V., Yadav, R., Jain, M., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1389971 · Cited by 41
Zhu, E., Yu, J., Li, Y.-R., Ma, F., Wang, Y.-C., Liu, Y., Li, M., Kim, Y. J., Zhu, Y., Hahn, Z., et al. (2024) · Nature Nanotechnology · doi:10.1038/s41565-024-01781-4 · Cited by 35
A non-conserved amino acid variant regulates differential signalling between human and mouse CD28
Porciello, N., Grazioli, P., Campese, A. F., Kunkl, M., Caristi, S., Mastrogiovanni, M., Muscolini, M., Spadaro, F., Favre, C., Nunès, J. A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03385-8 · Cited by 35
TCR–pMHC bond conformation controls TCR ligand discrimination
Sasmal, D. K., Feng, W., Roy, S., Leung, P. Q., He, Y., Cai, C., Cao, G., Lian, H., Qin, J., Hui, E., et al. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0273-6 · Cited by 34
Self-citationCalabretta, E., & Carlo‐Stella, C. (2020) · Cells · doi:10.3390/cells9040802 · Cited by 36
Balança, C.-C., Scarlata, C., Michelas, M., Devaud, C., Sarradin, V., Franchet, C., Gomez‐Roca, C., Gomez‐Roca, C., Tosolini, M., Heaugwane, D., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0855 · Cited by 39
The TLR4/ERK/PD‑L1 axis may contribute to NSCLC initiation
Kang, X., Li, P., Zhang, C., Zhao, Y., Hu, H., & Wen, G. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5068 · Cited by 34
Model membrane systems to reconstitute immune cell signaling
Céspedes, P. F., Beckers, D., Dustin, M. L., & Sezgin, E. (2020) · FEBS Journal · doi:10.1111/febs.15488 · Cited by 34
Gelsomino, L., Naimo, G. D., Malivindi, R., Augimeri, G., Panza, S., Giordano, C., Barone, I., Bonofiglio, D., Mauro, L., Catalano, S., et al. (2020) · Cancers · doi:10.3390/cancers12082078 · Cited by 34
Quantitative phosphoproteomic analysis reveals involvement of PD-1 in multiple T cell functions
Tocheva, A. S., Peled, M., Strazza, M., Adam, K. R., Lerrer, S., Nayak, S., Azoulay‐Alfaguter, I., Foster, C., Philips, E. A., Neel, B. G., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.014745 · Cited by 36
Sailer, N., Fetzer, I., Salvermoser, M., Braun, M., Brechtefeld, D., Krendl, C., Geiger, C., Mutze, K., Noeßner, E., Schendel, D., et al. (2022) · Cancers · doi:10.3390/cancers14081998 · Cited by 34
Robust T cell activation requires an eIF3-driven burst in T cell receptor translation
Silva, D. D., Ferguson, L., Chin, G. H., Smith, B. E., Apathy, R., Roth, T. L., Blaeschke, F., Kudla, M., Marson, A., Ingolia, N. T., et al. (2021) · eLife · doi:10.7554/elife.74272 · Cited by 32
Anti‐tumour potential of PD‐L1 / PD ‐1 post‐translational modifications
Zhou, S., Zhu, J., Xu, J., Gu, B., Zhao, Q., Luo, C., Gao, Z., Chin, Y. E., & Cheng, X. (2022) · Immunology · doi:10.1111/imm.13573 · Cited by 38
Self-citationWang, X., Zha, H., Wu, W., Yuan, T., Xie, S., Jin, Z., Long, H., Yang, F., Wang, Z., Zhang, A., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abn5029 · Cited by 34
Revolutionizing medicine with toll-like receptors: A path to strengthening cellular immunity
Malik, J. A., Kaur, G., & Agrewala, J. N. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127252 · Cited by 34
Effects of PD-1 Signaling on Immunometabolic Reprogramming
Boussiotis, V. A., & Patsoukis, N. (2022) · Immunometabolism · doi:10.20900/immunometab20220007 · Cited by 37
Mechanisms underlying response and resistance to immune checkpoint blockade in cancer immunotherapy
Lee, J., & Kim, E. H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1233376 · Cited by 36
Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy
Lecis, D., Sangaletti, S., Colombo, M. P., & Chiodoni, C. (2019) · Cancers · doi:10.3390/cancers11050624 · Cited by 33
Modeling immune cell behavior across scales in cancer
Makaryan, S. Z., Cess, C. G., & Finley, S. D. (2020) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1484 · Cited by 33
Chen, H., Moussa, M., & Catálfamo, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01223 · Cited by 33
Metadata
- Authors
- Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., & Vale, R. D.
- Affiliations
- Howard Hughes Medical Institute (US)
- Genentech (US)
- University of Chicago (US)
- Corresponding author
- Mellman, Ira
- Vale, Ronald D.
- ORCID
- Venue
- Science
- Published
- 2017-03-31
- Volume
- 355
- Issue
- 6332
- Pages
- 1428-1433
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC6286077
- OpenAlex
- W2592133876
- Cited by
- 1,689
- References
- 68
- Citations by year
- 2026: 121 · 2025: 158 · 2024: 201 · 2023: 203 · 2022: 193 · 2021: 218 · 2020: 224 · 2019: 159 · 2018: 143 · 2017: 63
- FWCI
- 70.99
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Science (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
- Funders
- Chicago Biomedical Consortium
- NIH (R21AI120010, R00AI106941)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- PD-1, CD28, PD-L1, T cell costimulation, T cell receptor signaling, SHP2, receptor dephosphorylation, T cell activation, anti-PD-1 therapy, cancer immunotherapy
- MeSH terms
- Animals, Humans, Immunotherapy, Lymphocyte Activation, Mice, Inbred C57BL, Neoplasms, Phosphorylation, T-Lymphocytes, CD28 Antigens, Jurkat Cells, Mice, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
